Stanford Cardiology Fellow | Stanford IM Residency | Vanderbilt MD/PhD | Philly sports | Homemade pasta and pizza | Girl Dad
Stanford, CA
Joined September 2010
- Tweets129
- Following189
- Followers155
- Likes826
Dr. Ramzi Dudum repping @StanCVFellows giving the state of the art on primary prevention, a topic near and dear to my heart #AHA23. Note-standing room only!
Brian Palmisano, MD, PhD retweeted
Come join the Knowles lab at Stanford! We study molecular mechanisms that mediate cardiovascular disease. There are several ongoing (funded) projects, and support to develop your own ideas! postdocs.stanford.edu/prospe…
@joshuawknowles @StanfordMed @StanfordOPA @StanfordDeptMed
Wow, entering a new era of prevention with once every six month medications lowering lipids and now blood pressure! 🤯🤯🤯
In this phase 1 study involving persons with hypertension, zilebesiran (an RNA interference therapeutic agent) was associated with decreases in angiotensin levels and systolic and diastolic blood pressure. Read the full study: nej.md/44N1IcX
Brian Palmisano, MD, PhD retweeted
Doc, can my LDL-C be *too low* after a heart attack?
Apparently, not.
- *achieved LDL-C < 20 mg/dl* with PCSK9i
- 5y therapy
- greatest benefit
- no more AEs
Remarkable!
ahajournals.org/doi/full/10.…
👏 @PrakritiGaba @DrM_ODonoghue
Brian Palmisano, MD, PhD retweeted
One week left to submit applications for the ACC/ABC Merck Research Fellowship Award!
These awards provide 3 one-year fellowships in the amount of $100K each to be awarded as salary support for 1 year of research in adult cardiology. Apply today: bit.ly/3KEk08W
As somebody who did basically an entire PhD on new functions of CETP beyond HDL (with @TheStaffordLab), all I have to say is:
“Wow!”
And
“How???”
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin ther... sciencedirect.com/science/ar… @nationallipid @ProfSNicholls @JohnKastelein @mdavidsonmd 63.4% reduction in LDL-c, 55.6 % Non-HDL-c with obicetrapib plus ezetimibe!
🤯 Incredible! Seems like it wasn’t that long ago you guys were just starting out! Bravo!
The Dean’s Award for Research honors outstanding physician scientists. Congratulations! @BReinfeld @MargaretAxelrod @madden_mz
ALT Three students pose with two deans
Brian Palmisano, MD, PhD retweeted
Thanks @joshuawknowles and @B_palms for a very clear and clinician “friendly” chapter on polygenic risk scores for preventive cardiology!
Homemade spaghetti with pistachios, tomato and mint courtesy of @177MilkStreet.
Interesting how rare ODS is in hypoNa. Maybe we can relax a little bit for these admissions??
Osmotic demyelination syndrome (ODS) following correction of hyponatremia was studied in 22,858 hospitalizations. There were 12 cases of ODS identified, only half of which occurred following rapid correction of serum sodium. #IMTwitter #NeuroTwitter
Brian Palmisano, MD, PhD retweeted
🧵on our sitting #PURE paper led by @li_sidong in @JAMACardio: bit.ly/3hBIpAb
106K people from 21 countries followed for 11 yrs.
Siting >8 hr/day associated with:
20%⬆️risk for early death
29%⬆️risk for cardiac death
17% ⬆️risk for non-cardiac death
#health #exercise
Kind of wild the entire NFC East would make the playoffs at this point. Fly eagles fly! #GoBirds 🦅🦅
Brian Palmisano, MD, PhD retweeted
I just want to make a few things clear:
The Holocaust happened.
Hitler was a demonic figure.
And instead of giving it a platform, our political leaders should be calling out and rejecting antisemitism wherever it hides.
Silence is complicity.
Why are we devoting time and money to trials comparing meds in the same class with the same mechanism?? Torsemide vs furosemide and HCTZ vs chlorthalidone. #AHA22
Raise your hand if you expected a significant difference in either trial. I’ll wait…
Brian Palmisano, MD, PhD retweeted
Even @Oprah (who made Dr. Oz's TV career) knows
today.com/news/elections/opr…
To think that in 2022 we would have a Supreme Court willing to revisit the constitutionality of affirmative action is mind boggling to me. #dumbfounded
Brian Palmisano, MD, PhD retweeted
our family will never buy from @adidas again.